News | September 05, 2025
Quotient Sciences and CPI join forces to accelerate RNA drug development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
